Stiefel Laboratories, Inc. has enlisted the advisory arm of Blackstone Group for assistance with the sale of the company, according to a source. The privately held U.S. pharmaceutical company is the world's largest independent dermatology company and its value is estimated at more than $3 billion.
Blackstone, which owns a substantial minority stake in Stiefel, has begun contacting parties regarding the sale, according to a source. The Wall Street Journal first reported that Stiefel was considering selling itself in a deal that could be worth several billions of dollars. Officials at Stiefel and Blackstone have not commented on the arrangement.